RALEIGH, North Carolina, June 5, 2026
VetrixBio has announced encouraging first clinical data for VTX-304, its investigational first-in-class bispecific antibody designed to treat canine osteoarthritis (OA) by simultaneously targeting nerve growth factor (NGF) and ADAMTS-5, two critical drivers of pain and cartilage degradation. The findings were presented at the 6th International Veterinary Pain Short Course hosted by NC State College of Veterinary Medicine, highlighting a potentially transformative approach to managing one of the most common chronic diseases affecting dogs worldwide. Osteoarthritis impacts millions of companion animals, causing persistent pain, reduced mobility, and progressive joint damage. Unlike existing therapies that primarily focus on symptom management, VTX-304 is designed to address both pain relief and cartilage protection in a single molecule, positioning it as a potential disease-modifying therapy capable of altering the course of canine osteoarthritis. The results mark an important milestone for VetrixBio as it advances a pipeline of innovative biologics aimed at addressing major unmet needs in veterinary medicine.
Dual-Target Antibody Demonstrates Strong Clinical and Biological Activity
The clinical data were generated using a natural osteoarthritis model involving aged Beagles with a mean age of 10.8 years. Dogs receiving VTX-304 at a dose of 2.5 mg/kg administered subcutaneously achieved pain relief comparable to bedinvetmab, a commercially established anti-NGF monoclonal antibody therapy. Pain reduction was measured using the modified Canine Brief Pain Inventory (mCBPI), a widely recognized assessment tool in veterinary pain research. Beyond symptom relief, laboratory and cell-based analyses demonstrated that VTX-304 effectively inhibited both the NGF/TrkA signaling pathway, responsible for pain sensitization, and ADAMTS-5-mediated aggrecan cleavage, a key mechanism underlying cartilage destruction in osteoarthritis.
These findings provide compelling evidence that the bispecific antibody may offer a differentiated therapeutic profile by targeting multiple aspects of disease biology simultaneously. Researchers emphasized that the dual mechanism approach could provide broader clinical benefits than currently available therapies that focus exclusively on pain management.
Addressing a Major Unmet Need in Veterinary Medicine
Advertisement
Osteoarthritis remains one of the most significant health challenges affecting aging dogs, with current treatment options largely limited to nonsteroidal anti-inflammatory drugs (NSAIDs) and anti-NGF therapies. While these treatments can reduce discomfort, they do not directly address the progressive cartilage degeneration that drives long-term joint deterioration. VTX-304 was specifically engineered to combine the proven analgesic effects of NGF inhibition with the cartilage-protective potential of ADAMTS-5 blockade, creating an integrated strategy for both symptom control and disease modification. Scientific evidence suggests that ADAMTS-5 is the dominant enzyme responsible for the breakdown of aggrecan, a critical structural component of healthy cartilage.
By simultaneously suppressing this pathway and reducing pain signaling, VTX-304 may help preserve joint function while improving quality of life. Company scientists noted that anti-ADAMTS-5 antibodies have demonstrated preferential distribution to cartilage tissue, supporting the possibility of sustained activity within diseased joints following subcutaneous administration.
Potential First Disease-Modifying Osteoarthritis Drug for Dogs
The positive data reinforce VetrixBio’s vision of developing next-generation biologic therapies for companion animals. The company believes VTX-304 has the potential to become the first disease-modifying osteoarthritis drug (DMOAD) for canine patients, a category long sought by veterinary researchers and clinicians. By targeting both pain and the underlying drivers of cartilage destruction, the therapy could extend mobility, preserve joint health, and improve long-term outcomes for dogs living with osteoarthritis.
The results also underscore the growing role of advanced biologics and antibody engineering within veterinary medicine, where innovative treatment options remain limited compared with human healthcare. As development progresses, VTX-304 could represent a significant advancement in companion animal therapeutics, offering veterinarians a novel tool to address one of the most prevalent and debilitating chronic conditions affecting dogs while helping pets maintain healthier, more active lives for longer periods.
Source: VetrixBio press release
